Literature DB >> 205345

Production of plasminogen activator by cells transformed by herpesviruses.

M K Howett, C S High, F Rapp.   

Abstract

Plasminogen activator is produced by hamster cells transformed by human herpesviruses. These cell lines have previously been shown to be oncogenic when injected s.c. into newborn syngeneic hamsters. Lysis of fibrin overlays by these cell lines was plasminogen dependent. Normal hamster embryo fibroblasts and a hamster cell line transformed by PARA-7 (an adenovirus-SV 40 hybrid) failed to produced lysis. In separate experiments fibrin overlay of lytically infected secondary rabbit kidney cells did not show induction of this activity during the normal course of productive infection. The human cell line TE-85 clone F-5, a clonal cell line from a human osteogenic sarcoma, failed to produce plasminogen activator, but two separate clones of these cells that were morphologically transformed after exposure to UV-inactivated herpes simplex virus type 2 produced rapid lysis of the fibrin overlay. Clonal variation was observed in herpes simplex virus types 1 and 2-transformed hamster lines and is under investigation. It is suggested that plasminogen activator detection may serve as a convenient assay system for transformation of normal cells by herpesviruses.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 205345

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Production of plasminogen activator by human and hamster cells infected with human cytomegalovirus.

Authors:  K Yamanishi; F Rapp
Journal:  J Virol       Date:  1979-08       Impact factor: 5.103

2.  Hormonal regulation of plasminogen activator and peroxidase activities in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors and the rat uterus.

Authors:  K Inada; J Yamashita; T Yoshimura; S Matsuo; Y Nakashima; S Yamashita; A Misumi; M Ogawa
Journal:  Jpn J Surg       Date:  1991-03

Review 3.  Tumor invasion and host extracellular matrix.

Authors:  B U Pauli; D E Schwartz; E J Thonar; K E Kuettner
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

Review 4.  The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.

Authors:  J E Testa; J P Quigley
Journal:  Cancer Metastasis Rev       Date:  1990-12       Impact factor: 9.264

5.  Protease-activated "prodrugs" for cancer chemotherapy.

Authors:  P L Carl; P K Chakravarty; J A Katzenellenbogen; M J Weber
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

6.  Loss of surface fibronectin after infection of cultured cells by HSV-1 and 2.

Authors:  H P Dienes; A Knoblich; D Falke
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

7.  Tumorigenicity of herpesvirus-transformed cells correlates with production of plasminogen activator.

Authors:  S F Adelman; M K Howett; F Rapp
Journal:  Mol Cell Biol       Date:  1981-05       Impact factor: 4.272

8.  Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme.

Authors:  K Kaltoft; L S Nielsen; J Zeuthen; K Danø
Journal:  Proc Natl Acad Sci U S A       Date:  1982-06       Impact factor: 11.205

9.  Activation of plasminogen to plasmin by a protease associated with the outer membrane of Escherichia coli.

Authors:  S P Leytus; L K Bowles; J Konisky; W F Mangel
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

10.  Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancer.

Authors:  J Yamashita; M Ogawa; S Yamashita; Y Nakashima; T Saishoji; K Nomura; K Inada; I Kawano
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.